Show simple item record

dc.contributor.authorPellinen, Teijo 
dc.contributor.authorBlom, Sami
dc.contributor.authorSanchez, Sara 
dc.contributor.authorValimaki, Katja
dc.contributor.authorMpindi, John-Patrick
dc.contributor.authorAzegrouz, Hind 
dc.contributor.authorStrippoli, Raffaele 
dc.contributor.authorNieto-Arellano, Rocio 
dc.contributor.authorViton, Mariano 
dc.contributor.authorPalacios, Irene 
dc.contributor.authorTurkki, Riku
dc.contributor.authorWang, Yinhai
dc.contributor.authorSanchez-Alvarez, Miguel 
dc.contributor.authorNordling, Stig
dc.contributor.authorButzow, Anna
dc.contributor.authorMirtti, Tuomas
dc.contributor.authorRannikko, Antti
dc.contributor.authorMontoya, María 
dc.contributor.authorKallioniemi, Olli
dc.contributor.authordel Pozo, Miguel Angel 
dc.date.accessioned2018-11-22T08:10:54Z
dc.date.available2018-11-22T08:10:54Z
dc.date.issued2018
dc.identifierISI:000424087700010
dc.identifier.citationSci Rep. 2018; 8(1):2338
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6690
dc.description.abstractCaveolin-1 (CAV1) is over-expressed in prostate cancer (PCa) and is associated with adverse prognosis, but the molecular mechanisms linking CAV1 expression to disease progression are poorly understood. Extensive gene expression correlation analysis, quantitative multiplex imaging of clinical samples, and analysis of the CAV1-dependent transcriptome, supported that CAV1 re-programmes TGF beta signalling from tumour suppressive to oncogenic (i.e. induction of SLUG, PAI-1 and suppression of CDH1, DSP, CDKN1A). Supporting such a role, CAV1 knockdown led to growth arrest and inhibition of cell invasion in prostate cancer cell lines. Rationalized RNAi screening and high-content microscopy in search for CAV1 upstream regulators revealed integrin beta1 (ITGB1) and integrin associated proteins as CAV1 regulators. Our work suggests TGF beta signalling and beta1 integrins as potential therapeutic targets in PCa over-expressing CAV1, and contributes to better understand the paradoxical dual role of TGF beta in tumour biology.
dc.description.sponsorshipThis study was supported by grants SAF2011-25047 and CSD2009-0016 from Spanish Ministry of Science and Innovation (MICINN), SAF2014-51876-R from Spanish Ministry of Economy and Competitiveness (MINECO) and co-funded by FEDER funds, 674/C/2013 from Fundacio La Marato de TV3, and AICR 15-0404 from the Worldwide Cancer Research Foundation (to M.A.dP.), by BIO2014-62200-EXP (to M.M.) as well as from the Academy of Finland Center of Excellence in Translational Cancer Biology (251314), Sigrid Juselius Foundation, and Cancer Society of Finland (to O.K.). T.P. was funded by CNIC Postdoctoral Program and by the Academy of Finland Post-doctoral fellow position (253662). Additional funding was from Emil Aaltonen foundation, Wihuri foundations, and Magnus Ehrnrooth foundation (to T.P.). Montserrat Arroyo (CNIC Cellomics Unit) helped in performing the screening. The CNIC is supported by MINECO and the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0505). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.isversionofPublisher's version
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleITGB1-dependent upregulation of Caveolin-1 switches TGF beta signalling from tumour-suppressive to oncogenic in prostate cancer
dc.typeArtículo
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29402961
dc.format.volume8
dc.identifier.doi10.1038/s41598-018-20161-2
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)
dc.contributor.funderFundació La Marató
dc.contributor.funderWorldwide Cancer Research Foundation
dc.contributor.funderAcademy of Finland
dc.contributor.funderSigrid Juselius Foundation
dc.contributor.funderCancer Society of Finland
dc.contributor.funderCentro Nacional de Investigaciones Cardiovasculares
dc.contributor.funderEmil Aaltonen Foundation
dc.contributor.funderWihuri Foundations
dc.contributor.funderMagnus Ehrnrooth Foundation
dc.contributor.funderFundación ProCNIC
dc.description.peerreviewed
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-018-20161-2
dc.identifier.journalScientific Reports
dc.repisalud.orgCNICCNIC::Grupos de investigación::Señalización por Integrinas
dc.repisalud.orgCNICCNIC::Unidades técnicas::Celómica
dc.repisalud.institucionCNIC
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2011-25047es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CSD2009-0016es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SEV-2015-0505es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/BIO2014-62200-EXPes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional